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Summary
Background: Peritoneal metastasis arising from colorec-
tal cancer, appendiceal cancer, gastric cancer and gyne-
cologic malignancies, or primary peritoneal surface ma-
lignancies such as peritoneal mesothelioma and primary 
peritoneal adenocarcinoma may be efficiently treated by 
cytoreductive surgery (CRS) and hyperthermic intraperi-
toneal chemotherapy (HIPEC) in selected patients. 
Method: CRS is based on the technique of parietal and 
visceral peritonectomy and consists of multiple surgical 
procedures. HIPEC combines high local doses of cyto-
statics with the additional cytotoxic effects of hyperther-
mia. Results: The goal of CRS is to achieve a complete 
macroscopic cytoreduction (CC-0/1) as a precondition for 
consecutive HIPEC that should destroy residual tumor 
cells within the abdominal cavity. Conclusion: CRS and 
HIPEC can be performed with acceptable morbidity and 
low mortality in specialized centers. However, due to 
long learning curves, consistent surgical training is 
strongly recommended.
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Zusammenfassung
Hintergrund: Die zytoreduktive Chirurgie (CRS) und 
 hypertherme intraperitoneale Chemotherapie (HIPEC) 
 stellen eine effiziente Behandlungsoption für selektio-
nierte Patienten mit Peritonealkarzinose bei diversen gas-
trointestinalen Karzinomen und Ovarialkarzinom bzw. 
malignem peritonealen Mesotheliom oder primärem 
 Adenokarzinom des Peritoneums dar. Methode: Die CRS 
basiert auf der Technik der parietalen und viszeralen Peri-
tonektomie und beinhaltet multiple Prozeduren. Die 
HIPEC kombiniert hohe lokale Zytostatikadosen mit den 
additiven zytotoxischen Effekten der Hyperthermie. Er-
gebnisse: Ziel der CRS ist die komplette makrosko pische 
Zytoreduktion (CC-0/1) als Voraussetzung für die Durch-
führung einer intraoperativen HIPEC, die intraabdominell 
verbliebene Tumorzellen zerstören soll. Schlussfolge-
rung: CRS und HIPEC können in spezialisierten Zentren 
mit akzeptabler Morbidität und niedriger Mortalität 
durchgeführt werden. Aufgrund der langen Lernkurve 
sind jedoch eine strukturierte Ausbildung und ein ad-
äquates chirurgisches Training dringend zu empfehlen.
Introduction
Peritoneal metastasis is a common sign of advanced tumor 
stage, disease progression, or recurrence in numerous tumor 
entities of gastrointestinal or gynecological origin. Moreover, 
there are primary peritoneal malignancies such as malignant 
peritoneal mesothelioma or primary peritoneal carcinoma. 
Peritoneal tumor dissemination is still often associated with 
poor prognosis [1, 2]. The concept of cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy 
(HIPEC) as first described by Sugarbaker et al. [3] in 1989 
provides an additive promising treatment option for a se-
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in specialized centers for peritoneal surface malignancies is 
strongly recommended for CRS. Under these conditions, a 
learning curve ranging from 60 to 158 patients has been re-
ported for CRS (and HIPEC) to achieve acceptable safety 
and oncologic radicality [10].
Surgical Approach
The patient is placed in the modified lithotomy position 
that should be accurately controlled before surgery to avoid 
postoperative compartment syndrome of the lower leg with 
consecutive skin, muscle, and/or nerve injury. A complete me-
dian laparotomy is performed with a median skin incision 
from the xiphoid to the symphysis. Omphalectomy is not 
mandatory in all patients and should be performed depending 
on the primary tumor, tumor load, and dissemination pattern. 
However, in patients with high-volume pseudomyxoma peri-
tonei as well as patients with periumbilical scars after previous 
resection or exploration of malignant mesothelioma, ompha-
lectomy should be routinely performed. Especially in patients 
with malignant peritoneal mesothelioma, pseudomyxoma 
peritonei, and high tumor load, the integrity of the parietal 
peritoneum should be preserved to allow for easier extraperi-
toneal preparation and parietal peritonectomy. Skin sutures 
that are fixed on the frame of the retraction system and hold-
ing tension by clamps may facilitate this first step of surgical 
preparation. Following its exposure, the parietal peritoneum 
is incised and the abdominal cavity is accurately explored.
The extent of abdominal tumor dissemination is deter-
mined using the Peritoneal Cancer Index (PCI), a combined 
numerical score of lesion size (LS-0 to LS-3) and tumor loca-
tion (region 0–12) that ranges from 0 to 39 [8, 11]. The abdom-
inal exploration plays a pivotal role in intraoperative decision 
making regarding the indication for CRS and HIPEC. 
Whereas there are no PCI-associated limitations in patients 
with pseudomyxoma peritonei, based on the survival data in 
patients with peritoneal disease from colorectal cancer the in-
traoperative PCI should be lower than 20 and in patients with 
gastric cancer at least lower than 10. Esquivel et al. [12, 13] 
have shown that preoperative CT scans often underestimate 
the intraoperative PCI. However, the extent of peritoneal dis-
ease and the probability to achieve a complete macroscopic 
cytoreduction (CC-0/1) define the oncological benefit of the 
combined treatment concept. Thus, exploration along the 
round ligament of the liver with dissection of the parenchy-
matic bridge between liver segments III and IVb (pont hépa-
tique) [14] and exploration of the omental bursa are manda-
tory. Beyond the technical feasibility of resection, histology, 
primary tumor, operative risk, pre- and postoperative quality 
of life, and patient preference have to be considered (fig. 1). 
The greater omentum is often infiltrated by tumor nodules 
and may appear as ‘omental cake’ (fig. 2). Moreover, it has 
been shown to be a frequent area of intra-abdominal disease 
recurrence in different tumor entities. Thus, surgical resection 
should start with infragastric greater omentectomy including 
lected group of patients with peritoneal tumor dissemination 
[3, 4]. Although there are only few prospective randomized 
trials, several studies and retrospective analyses could show 
that CRS and HIPEC as an integrative part of an interdiscipli-
nary treatment concept may improve the oncological outcome 
of selected patients with peritoneal metastasis [1, 5]. How-
ever, the multimodal treatment is associated with significant 
adverse effects. By analyzing the data from 24 international 
specialized centers, Chua et al. [6] reported a mean grade III/
IV morbidity and mortality rate of 28.8 and 2.9%, respec-
tively. The following article summarizes the surgical ap-
proach, intraoperative decision making, and selected technical 
aspects regarding peritonectomy procedures and HIPEC.
Cytoreductive Surgery
CRS consists of numerous surgical procedures depending 
on the extent of peritoneal tumor manifestation. Surgery may 
include parietal and visceral peritonectomy, greater and lesser 
omentectomy, and single organ as well as multivisceral resec-
tion. Moran et al. [7] described the following five basic proce-
dures: i) right hemicolectomy, greater and lesser omentec-
tomy, and splenectomy; ii) right and left diaphragmatic peri-
tonectomy; iii) cholecystectomy and resection of Glisson’s 
capsule; iv) (partial) gastrectomy; and v) anterior rectal resec-
tion, pelvic peritonectomy, hysterectomy, and ovariectomy. 
The goal of CRS is to remove all visible intraperitoneal tumor 
nodules. The completeness of cytoreduction can be deter-
mined by the completeness of the cytoreduction score. CC-0 
indicates no visible residual tumor and CC-1 residual tumor 
nodules )2.5 mm. CC-2 and CC-3 indicate residual tumor 
nodules between 2.5 mm and 2.5 cm and >2.5 cm, respectively 
[8]. Nevertheless, as single tumor nodules )2.5 mm within the 
abdominal cavity may remain unnoticed during surgery, espe-
cially in patients with a high tumor load, a complete macro-
scopic cytoreduction as a precondition for HIPEC is classified 
as CC-0/1 by most surgical oncologists. 
Surgical Technique
Peritonectomy procedures qualify for numerous surgical 
techniques and the use of multiple different instruments. At 
least, monopolar electrosurgery and bipolar coagulation for-
ceps are recommended. Additional instruments such as bipo-
lar scissors, argon beam, or tissue sealing devices may be help-
ful. Preparation may be performed by sharp and blunt dissec-
tion depending on the procedure, the surgeon’s preferred 
technique, and the individual intraoperative findings. The 
technique is based on the principle of traction and counter-
traction that allows for parietal as well as visceral peritoneal 
stripping [9]. In contrast to the standard procedure, some 
organ resections such as splenectomy, rectal resection, or hys-
terectomy have to be performed via an extraperitoneal ap-
proach. Consistent surgical tutoring by specialists and training 
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to tumor nodules on the peritoneum of the gall bladder and 
allows for easier access to the right subhepatic space (Morri-
son’s pouch). In the case of tumor infiltration of the dia-
phragm, en bloc resection with consecutive suture of the dia-
phragm may be necessary. In these cases, intraoperative 
placement of a chest tube may help to avoid postoperative 
respiratory problems caused by pleural effusion. Additional 
hepatobiliary procedures such as extensive resection of the 
Glisson’s capsule, liver resection, or bile duct resection may 
be necessary to obtain complete macroscopic cytoreduction 
and do not increase morbidity and mortality rates in experi-
enced centers [15]. 
Peritonectomy of the left upper quadrant may be per-
formed with or without splenectomy depending on the distri-
bution pattern of the peritoneal implants. Thus, accurate ini-
tial exploration of the spleen is crucial to avoid residual tumor 
nodules in the left upper quadrant. The peritoneum is stripped 
from beneath the left diaphragm. If splenectomy is necessary, 
the spleen is mobilized via a lateral extraperitoneal approach 
and resected en bloc with the peritoneum of the left upper 
quadrant. Injury of the pancreatic tail should be avoided.
resection of the right gastroepiploic vessels. This step may 
free the abdomen from extensive tumor mass at the beginning 
of the operation and also allows for easier exploration and, if 
necessary, stripping of the omental bursa.
Right and Left Upper Quadrant
In the case of peritoneal metastasis affecting the right 
upper quadrant, the peritoneum must be stripped from be-
neath the right hemidiaphragm. Because tumor infiltration of 
the Glisson’s capsule may require additional liver capsule re-
section, this procedure should be performed at the beginning 
to avoid an increasing risk of bleeding by swelling of the liver 
during a protracted CRS. The right liver lobe should be com-
pletely mobilized and the liver hilus should be exposed to 
allow for hepatic bleeding control if necessary. Peritoneal 
stripping is performed in four steps: i) incision of the perito-
neum and separation of the right upper quadrant; ii) traction 
of the liver and stripping of the right diaphragm; iii) identifi-
cation and preservation of the superior caval vein; and iv) 
transsection along the inferior caval vein, right colonic flex-
ure, and duodenum. A cholecystectomy is often necessary due 
Fig. 1. Algorithm for intraoperative decision 
making.
Fig. 2. ‘Omental cake’ of colorectal origin: 
tumor infiltration of the greater omentum in a 
patient with peritoneal metastasis from colo-
rectal cancer A after partial incision (peritoneal 
window) and B after complete incision of the 
parietal peritoneum.
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toneal mesothelioma, childbearing after CRS and HIPEC is 
possible [20]. Thus, this issue has to be conscientiously dis-
cussed with fertile female patients before surgery.
Hyperthermic Intraperitoneal Chemotherapy
As a second step of the multimodal treatment concept, 
HIPEC is performed after complete macroscopic cytoreduc-
tion (CC-0/1). The goal of this treatment is to destroy residual 
tumor cells by the additive effects of high local doses of cyto-
statics and hyperthermia which has been shown to improve 
tissue penetration of different cytostatic agents and may lead 
to direct cytotoxic effects [21, 22]. In the standard technique 
described by Paul H. Sugarbaker in 1995 [9], four drains are 
inserted intraperitoneally. The inflow drain is placed on the 
liver surface and three outflow drains are placed in the right 
and left subdiaphragmatic space and in the small pelvis, re-
spectively. Depending on the used HIPEC device and drain-
age set, the number of drains may vary. The perfusate is ap-
plied via a heating and circulating pump system, and the tem-
perature is monitored during the procedure. The intraperito-
neal temperature should reach 41–42 °C. Perfusion can be 
performed in an open, semi-open, or closed technique, de-
pending on the standard operating procedures of the special-
ized center. The theoretical advantage of the open technique 
is a better control of the circulation and uniform distribution 
of the cytostatic agents. An important disadvantage might be 
the increased risk of contamination compared to the closed 
abdomen technique. Although a comparison of the existing 
studies is difficult, there seem to be no significant differences 
between the two techniques regarding morbidity and mortal-
ity rates as well as patient survival [23]. The safety of HIPEC 
for the therapist and the assisting personnel has been proven 
[24, 25].
In the case of diaphragmatic tumor infiltration with con-
secutive diaphragmatic resection during CRS, additional per-
fusion of the thorax might be discussed. The diaphragm could 
be left open and reconstructed after HIPEC. A chest tube 
might be integrated in the perfusion cycle. This procedure is 
also applicable in the case of perfusate loss during HIPEC 
due to insufficient primary suture of a diaphragmatic lesion. 
However, there is no consistent data showing a higher risk of 
local recurrence after primary closure of the defect without 
thoracic perfusion.
The specific HIPEC protocol depends on the tumor entity 
and the standard operating procedures of the specialized 
center. To date, the cytostatic agents, combinations and con-
centrations, as well as perfusion times for HIPEC, are not 
well standardized. Thus, numerous different combinations of 
cytostatic agents are used. Perfusion times range from 30 to 
120 min [26]. Based on promising survival data for colorectal 
cancer, bidirectional oxaliplatin-based protocols that consist 
of intravenous application of 5-fluorouracil (5-FU) and folinic 
Lesser Omentum and Omental Bursa
A failure analysis in 42 out of 118 patients with pseu-
domyxoma peritonei published by Zoetmulder et al. [16] 
showed that the most frequent site of recurrence after CRS 
and HIPEC is the subhepatic and lesser omentum area (28%). 
Thus, an accurate exploration and surgical resection tech-
nique in this area plays a pivotal role regarding disease recur-
rence and oncological outcome of the patients. Since the right 
gastroepiploic vessels will have been ligated and resected dur-
ing greater omentectomy, the left gastric artery should be pre-
served during lesser omentectomy to avoid gastrectomy due 
to iatrogenic ischemia. However, in patients with gastric can-
cer or gastric tumor infiltration of other origin, total gastrec-
tomy might be performed in order to achieve a complete mac-
roscopic cytoreduction while considering the postoperative 
impairment of quality of life. In many cases, partial gastrec-
tomy, especially antrectomy, is sufficient for complete re-
moval of all visible tumor nodules. Piso et al. [17] demon-
strated no leakages related to gastric resections during CRS 
and HIPEC and acceptable postoperative morbidity in 37 pa-
tients. In some cases, an atypical left hepatic artery may arise 
from the left gastric artery that should be identified and 
preserved. 
Small Pelvis
The small pelvis is frequently affected by peritoneal tumor 
implants. Moreover, the primary tumor such as ovarian can-
cer, sigmoid or rectal cancer, or in some cases appendiceal 
cancer may be located in or near to the small pelvis. Thus, 
peritonectomy of the small pelvis is a common procedure dur-
ing CRS. The first step of pelvic peritonectomy is stripping 
the peritoneum from the posterior bladder wall. The urachus 
may be used as leading structure to start the peritonectomy. 
In the case of infiltration of the bladder, the affected part of 
the posterior wall should be resected and consecutively closed 
by interrupted sutures. When stripping the lateral wall of the 
small pelvis, the ureter has to be identified, mobilized, and 
preserved on both sides. In women, hysterectomy is often re-
quired to achieve complete macroscopic cytoreduction. For 
complete pelvic peritonectomy, the peritoneum is resected en 
bloc with the rectum including the Douglas pouch. Neverthe-
less, depending on the primary tumor and the dissemination 
pattern of tumor nodules, a Douglas pouch resection with rec-
tal preservation may be performed. 
In the case of peritoneal metastasis from ovarian cancer, 
ovariectomy with central ligation of the ovarian vessels, hys-
terectomy, and interaortocaval and iliac lymph node dissec-
tion are recommended [18]. Evers et al. [19] could show that 
at least 52% of patients with confirmed peritoneal metastases 
of colorectal or appendiceal origin have synchronous ovarian 
metastases. Based on these findings, ovariectomy should also 
be performed in women with peritoneal metastasis of colorec-
tal or appendiceal origin [19]. However, as reported in 5 pa-
tients with pseudomyxoma peritonei and 2 patients with peri-
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Conclusion
CRS and HIPEC should be considered as an efficient ther-
apeutic option for selected patients with peritoneal surface 
malignancies within an interdisciplinary treatment concept. 
The multimodal approach can be performed with acceptable 
morbidity and low mortality in specialized centers. Neverthe-
less, due to long learning curves, consistent surgical tutoring 
and training is strongly recommended. Several technical as-
pects as well as oncological and surgical outcome and individ-
ual patient factors should be taken into account before and 
during surgery.
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acid prior to intraperitoneal application of heated oxaliplatin 
are increasingly used [27, 28]. Initial data suggest that the in-
tensified protocol does not increase perioperative morbidity 
[29]. However, evidence from prospective randomized trials is 
missing. The HIPEC protocol should be chosen on an indi-
vidual basis considering tumor entity, response to previous 
chemotherapy regimens, and patient factors such as co-mor-
bidities. The current standard HIPEC protocols of the Uni-
versity Medical Center Regensburg are summarized in table 
1. Nevertheless, as long as consistent data from randomized 
controlled trials or comparative studies are missing, specific 
HIPEC protocols may not be generally recommended.
Entity Agent Dose, mg/m2 IP IV Perfusion
CRC
Appendiceal cancer
PMP
5-FU
folinic acid
oxaliplatin
400
 20
300 X
X
X 30 min
Gastric cancer
Ovarian cancer
Peritoneal mesothelioma
cisplatin
doxorubicin
 75
 15
X
X 60 min
IP = Intraperitoneal; IV = intravenous; CRC = colorectal cancer, PMP = pseudomyxoma peritonei.
Table 1. Current HIPEC protocols of the Uni-
versity Medical Center Regensburg based on 
different tumor entities; protocols may be mod-
ified due to individual patient factors, and as 
there is no standardization and no consistent 
data, other HIPEC protocols may be used fol-
lowing the standard operating procedures 
(SOP) of the treating peritoneal cancer center
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